Pharmaceutical firms are urged to capitalise on current trends in AD trials. The atopic dermatitis (AD) market is projected ...
Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...
Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...
The atopic dermatitis (AD) market is projected to reach $16.7 billion by 2030, according to GlobalData. New therapies like ...
GlobalData on MSN2d
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trialAclaris Therapeutics has dosed the first subject in the Phase IIa clinical trial of ATI-2138 to treat moderate to severe ...
Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.
The Asian Parent on MSN7d
Atopic Dermatitis in Kids: What Every Parent Should KnowAtopic dermatitis, a chronic skin condition, is common in children and requires treatment to minimise frequent flares. Dr Ker ...
The U.S. Food and Drug Administration has approved Elanco Animal Health's skin disease treatment for dogs, the health ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; "Zai Lab") today announced that data from a preclinical study of ZL-1503, the ...
ADESOS Phase 2b results with orismilast in atopic dermatitis (AD) selected as late-breaking oral presentation Additionally, two posters on data from the pioneering use of ...
1d
Elanco Animal Health Inc. (ELAN) announced the U.S. Food and Drug Administration has approved Zenrelia, a convenient once-daily oral ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback